Repetitive transcranial magnetic stimulation (rTMS) is known to be a safe, noninvasive, treatment for major depressive disorder (MDD), but how does cost compare with that of pharmacotherapy?.

 

Australian researchers compared the cost-effectiveness of rTMS with pharmacotherapy in treatment-resistant patients with MDD (ie, those who have failed at least 2 courses of antidepressant therapy).1 They found that, although both pharmacotherapy and rTMS are clinically effective, rTMS is more cost-effective.

Considering that up to 40% of patients with MDD either do not respond to or tolerate pharmacotherapy and that up to 85% of patients who do respond can be expected to relapse within 15 years, exploration of methods that more economically sustain quality of life is worthwhile.

Read story bellow by clicking the link. 

http://www.psychiatrictimes.com/major-depressive-disorder/tms-cost-effective/page/0/1